This trial is terminated!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Ischemic Cardiomyopathy or Coronary Artery Disease
and you are
over 18
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

The primary objective of this study is to demonstrate the feasibility and safety of intra-operative, intra-myocardial injection of autologous CD133 positive bone marrow cells at the time of coronary artery bypass graft (CABG) surgery in patients with chronic ischemic cardiomyopathy. Additionally, the feasibility of producing autologous CD133+ bone marrow stem cells will be assessed. The investigators hypothesize that collection of a sufficient number of CD133+ cells through bone marrow aspiration prior to surgery, with subsequent processing and intra-myocardial injection of high purity cells following completion of CABG, will be feasible without significant adverse clinical consequences.

Provided treatments

  • Device: Autologous CD133+ Bone Marrow Stem Cells
  • Other: Carrier Solution

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01721902. The sponsor of the trial is Miltenyi Biotec, Inc. and it is looking for 23 volunteers for the current phase.
Official trial title:
Stem Cell Implantation in Patients Undergoing CABG